Startups
MimiVax is a clinical-stage immunotherapy company developing SurVaxM, a survivin-targeting vaccine, for glioblastoma and other cancers.
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 12, 2024 | MimiVax Raises Funding | MimiVax, a NYC-based biotechnology company focused on the development of SurVaxM, a survivin-targeted vaccine therapy for glioblastoma and other cancers, raised an undisclosed amount in funding. The round saw participation from Brain Tumor ... |
| Nov 15, 2021 | MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma | BUFFALO, N.Y., Nov. 15, 2021 /PRNewswire/ -- MimiVax LLC, a clinical-stage biotechnology company in Buffalo, NY, USA, developing immunotherapeutics for cancer and autoimmune diseases, announced today that the company has received a "St... |
| US FDA awards Supplemental Orphan Drug Designation to SurVaxM to now include treatment of Malignant Glioma | The U.S. Food and Drug Administration (FDA) has granted supplemental orphan-drug designation (ODD) to SurVaxM for use in patients with malignant gliomas. New orphan designation broadens the patient population for potential use of SurVaxM to... |
Reviews 0
FAQ about MimiVax
What has the press written about MimiVax?
Parsers VC has collected 4 articles mentioning MimiVax, among them “MimiVax Raises Funding” (Jan 12, 2024) and “MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma” (Nov 15, 2021).
Is MimiVax still active?
Yes, MimiVax is active; its latest activity on Parsers VC dates from Jul 18, 2025.